Truist initiated coverage of Harmony Biosciences (HRMY) with a Buy rating and $48 price target Truist sees unrealized value in the stock for the base business alone, and expects the Wakix narcolepsy franchise growth to continue until its loss of exclusivity, generating more than $1B by 2027, the analyst tells investors in a research note. The firm sees several potential future growth levers with Wakix life-cycle management and new formulations, and the expanding clinical pipeline.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HRMY:
- Buy Rating Reaffirmed for Harmony Biosciences Amid Promising Orexin-2 Developments and Takeda’s Phase 3 Success
- Harmony Biosciences price target raised to $55 from $54 at Deutsche Bank
- Harmony Biosciences resumed with a Neutral at Goldman Sachs
- Harmony Biosciences Reveals Promising Preclinical Data for BP1.15205
- Harmony Biosciences presents preclinical data for BP1.15205